OncoSec Medical Incorporated (ONCS) Announces Issuance of Patents for ImmunoPulse® Platform

0
268

OncoSec Expands Intellectual Property Estate, Announces Issuance of Patents for ImmunoPulse® Platform

The first patent, JP06174632, encompasses a device for post-resection electroporation (“EP”) delivery of an agent (including nucleic acids) to prevent recurrence of resected tumors and expires in 2030. The patent family was added to the Company’s portfolio as part of a 2011 asset purchase agreement.

The second patent, US 9,610,634, adds to the ImmunoPulse® IL-12 portfolio, and includes coverage for reducing tumor angiogenesis while increasing T cell proliferation by the EP delivery of plasmid encoded IL-12.  The second patent expires in 2025.

“OncoSec is continuing to build a broad portfolio of patent assets encompassing compositions of matter and methods of use across diverse oncology applications with compelling unmet needs,” said Daniel J. O’Connor, Chief Executive Officer of OncoSec.  “We are pleased with the progress of the ongoing PISCES/KEYNOTE-695 clinical trial which benefits, in part, from the second issued patent.”

About Metastatic Melanoma1

Melanoma is a type of skin cancer that begins in skin cells called melanocytes. As the cancer progresses, melanoma becomes more difficult to treat once it spreads beyond the skin, such as the lymphatic system (metastatic disease). Given its occurrence young individuals, the potential years of life lost to melanoma can be higher when compared with other cancers. Although melanoma is a rare form of skin cancer, it accounts for over 75% of skin cancer deaths. The American Cancer Society estimates that approximately 87,000 new melanoma cases and 10,000 deaths from the disease will occur in the United States in 2017. Additionally, the World Health Organization estimates that approximately 132,000 new cases of melanoma are diagnosed around the world every year.

1 American Cancer Society (https://www.cancer.org/cancer/melanoma-skin-cancer/about/key-statistics.html); World Health Organization (http://www.who.int/uv/faq/skincancer/en/index1.html)

About PISCES (Anti-PD-1 IL-12 Stage III/IV Combination ElectroporationStudy)/KEYNOTE-695

PISCES/KEYNOTE-695 is a global, multicenter phase 2b, open-label trial of intratumoral plasma encoded IL-12 (tavokinogene telseplasmid or “tavo”) delivered by electroporation in combination with intravenous pembrolizumab in patients with stage III/IV melanoma who have progressed or are progressing on either pembrolizumab or nivolumab treatment. The Simon 2-stage study of intratumoral tavo plus electroporation in combination with pembrolizumab will enroll approximately 48 patients with histological diagnosis of melanoma with progressive locally advanced or metastatic disease defined as Stage III or Stage IV. The primary endpoint will be the Best Overall Response Rate (BORR).

To learn more about the trial, visit www.oncosec.com. Additional details can also be found at www.clinicaltrials.gov via NCT03132675

About OncoSec Medical Incorporated

OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse®, for the treatment of cancer. ImmunoPulse is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or “tavo”). In Phase 1 and 2 clinical trials, ImmunoPulse® IL-12 has demonstrated a favorable safety profile, evidence of anti-tumor activity in the treatment of various solid tumors, and the potential to reach beyond the site of local treatment to initiate a systemic immune response. OncoSec’s lead program, ImmunoPulse IL-12, is currently in clinical development for metastatic melanoma and triple-negative breast cancer. The program’s current focus is on the significant unmet medical need in patients with melanoma who are refractory or have relapsed on anti-PD-1 therapies. In addition to tavo, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse platform. For more information, please visit www.oncosec.com.

LEAVE A REPLY

Please enter your comment!
Please enter your name here